Amgen Says Enbrel Protected By Legit Patents, Rulings

By Bryan Koenig · January 9, 2025, 8:44 PM EST

Amgen has asked a Virginia federal judge to permanently toss the latest version of a proposed class action accusing it of illegally entrenching and expanding patent rights to stave off cheaper...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

Carefirst of Maryland, Inc. et al v. Amgen, Inc. et al

Case Number

Court

Virginia Eastern

Nature of Suit

Anti-Trust

Date Filed

August 06, 2024

Recent Articles By Bryan

January 03, 2025
DOJ Wants Oct. Amedisys Trial, UnitedHealth Wants Aug.
December 19, 2024
FTC Says PBMs Can't Get Preliminary Block In Insulin Case
December 03, 2024
PE-Backed Anesthesia Giant Can't Duck Antitrust Claims
November 15, 2024
PBMs Denied Breakup Of Combined FTC Insulin Price Trial
November 13, 2024
Outgoing DOJ Antitrust Head Wants To Unstack Healthcare
November 12, 2024
HIV Drug Buyers Want Gilead Product Switch Claims Revived
November 12, 2024
Unsatisfied With $70M UTC Win, Sandoz Appeals To 3rd Circ.
November 07, 2024
Same PBM Conduct Means Same Insulin Price Trial, FTC Says
October 21, 2024
PBMs Keep Door Open To Constitutional Riposte Against FTC
October 16, 2024
Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong